| It talk about Tarceva | | | | compared to placebo. |
| In year 2004, The U.S Food and Drug Administration | | | | For those patient’s tumours did not have an |
| (FDA) approved a Tarceva for the treatment of | | | | EGFR mutation, It show a 30% improvement in |
| advance non small cell lung cancer, a pill to treat a | | | | survival. The majority of patients with NSCLC do not |
| lung cancer patient. Tarceva was approved for | | | | have EGFR mutation and are known as EGFR |
| patients with advanced non-small cell lung cancer, | | | | wild-type. |
| who have failed to respond to at least one prior of | | | | Tarceva is a small molecule inhibitor of the epidermal |
| chemotherapy. Scientist study shows that it delayed | | | | growth factor receptor (EGFR), is currently marketed |
| the progression of advanced lung cancer and live | | | | for the lung cancer treatment of patients with locally |
| longer when use as a single agent, those patients | | | | advanced or metastatic non-small cell lung cancer |
| who did not progress following first line treatment. | | | | (2nd line NSCLC) after the first line treatment failure |
| Scientist study showing that Tarceva extended the | | | | of at least one prior chemotherapy regimen and |
| patients with advanced non small cell lung cancer a | | | | pancreatic cancer. |
| clinical trials by a median of 6.7 months compared to | | | | Previously, Tarceva had competed with |
| 4.7 months for patients who got a placebo , 31 | | | | AstraZeneca’s drug Geftinib, Geftinib (Iressa) |
| percent of the patients taking tarceva were still alive | | | | drug was approved for the same treatment. But the |
| compared to 22 percent of those taking the placebo. | | | | drug show in a study was unsuccessful in improving |
| Patients with non small cell lung treat with Tarceva | | | | survival. Gefitinib is non longer an active option for |
| had a 23%improvement in overall survival compared | | | | non-small cell lung cancer patients. |
| with patients who received placebo. Based on Saturn | | | | Recently, based on Roche Group study show that |
| date show that patients with advanced non small cell | | | | patients with advanced non-small cell lung cancer |
| lung cancer (NSCLC) who received Tarceva as a | | | | (NSCLC) who received Avastin (bevacizumab) and |
| first-line maintenance treatment had a 41% | | | | Tarceva (erlotinib) as combined first-line |
| improvement in the time they lived without the | | | | maintenance treatment had show positive result with |
| disease advancing (progression-free survival or PFS) | | | | 39 %t improvement. |